Has Race conducted any studies into how effective the cardioprotection provided by bisantrene is compared to the other cardioprotective drugs that are available/approved?
Has Race conducted any studies into whether bisantrene can protect any other areas of the body that can potentially be permanently damaged by chemotherapy of different kinds (e.g. reproductive organs, peripheral nerves, kidneys)?
Thanks in advance.
RAC media coverage, page-1913
-
- There are more pages in this discussion • 352 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
0.030(1.76%) |
Mkt cap ! $296.3M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.75 | $1.70 | $136.5K | 79.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 7267 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 6010 | 1 |
View Market Depth
| Last trade - 13.02pm 25/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |